AMGN

Phase 3 DECISION Trial of NEXAVAR (sorafenib) in Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Cancer Refractory to Radioactive Iodine Published in The Lancet

[PR Newswire] – WHIPPANY, N.J. and THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., April 23, 2014 /PRNewswire/ — Bayer HealthCare Pharmaceuticals Inc. and Onyx Pharmaceuticals, Inc., an Amgen subsidiary (Nasdaq: … moreView todays social media effects on AMGNView the latest stocks trending across Twitter. Click to view dashboardSee who Amgen is hiring next, click here to view […]

Amgen’s CEO Discusses Q1 2014 Results – Earnings Call Transcript

[Seeking Alpha] – I’d like to welcome you to our conference call to review our operating performance for the first quarter of this year. Our performance gives us confidence that we are on track to deliver our full year guidance. Bob will provide a brief moreView todays social media effects on AMGNView the latest stocks trending across Twitter. Click […]